S
Suma Krishnan
Publications - 9
Citations - 745
Suma Krishnan is an academic researcher. The author has contributed to research in topics: Lisdexamfetamine Dimesylate & Attention deficit hyperactivity disorder. The author has an hindex of 6, co-authored 9 publications receiving 709 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
TL;DR: Treatment once daily with the prodrug LDX at doses of 30 to 70 mg appeared to be effective and had a tolerability profile similar to those of currently marketed extended-release stimulants.
Journal ArticleDOI
Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Lenard A. Adler,David W. Goodman,Scott H. Kollins,Richard H. Weisler,Suma Krishnan,Yuxin Zhang,Joseph Biederman +6 more
TL;DR: All 3 lisdexamfetamine doses were significantly more effective than placebo in the treatment of adults with ADHD, with improvements noted within 1 week.
Journal ArticleDOI
Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study
Joseph Biederman,Samuel W. Boellner,Ann C. Childress,Frank A. Lopez,Suma Krishnan,Yuxin Zhang +5 more
TL;DR: In a laboratory classroom environment, LDX significantly improved ADHD symptoms versus placebo in school-age children with ADHD in an analog classroom setting.
Journal ArticleDOI
Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.
TL;DR: Long-term 30, 50, and 70 mg/day LDX was generally well tolerated and effective in children with ADHD.
Journal ArticleDOI
Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover study
TL;DR: The findings from this study in a small, select population of children with ADHD suggest that the concentrations of d-amphetamine, the active metabolite ofLDX, after single-dose administration of LDX at increasing doses appeared to be dose proportional and had low interpatient variability.